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Abstract
BACKGROUND—Stomach cancer was a leading cause of cancer-related deaths early in the 20th 
century and has steadily declined over the last century in the United States. Although incidence 
and death rates are now low, stomach cancer remains an important cause of morbidity and 
mortality in black, Asian and Pacific Islander, and American Indian/Alaska Native populations.
METHODS—Data from the CONCORD-2 study were used to analyze stomach cancer survival 
among males and females aged 15 to 99 years who were diagnosed in 37 states covering 80% of 
the US population. Survival analyses were corrected for background mortality using state-specific 
and race-specific (white and black) life tables and age-standardized using the International Cancer 
Survival Standard weights. Net survival is presented up to 5 years after diagnosis by race (all, 
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black, and white) for 2001 through 2003 and 2004 through 2009 to account for changes in 
collecting Surveillance, Epidemiology, and End Results Summary Stage 2000 data from 2004.
RESULTS—Almost one-third of stomach cancers were diagnosed at a distant stage among both 
whites and blacks. Age-standardized 5-year net survival increased between 2001 to 2003 and 2004 
to 2009 (26.1% and 29%, respectively), and no differences were observed by race. The 1-year, 3-
year, and 5-year survival estimates were 53.1%, 33.8%, and 29%, respectively. Survival improved 
in most states. Survival by stage was 64% (local), 28.2% (regional), and 5.3% (distant).
CONCLUSIONS—The current results indicate high fatality for stomach cancer, especially soon 
after diagnosis. Although improvements in stomach cancer survival were observed, survival 
remained relatively low for both blacks and whites. Primary prevention through the control of 
well-established risk factors would be expected to have the greatest impact on further reducing 
deaths from stomach cancer.
Keywords
cancer registries; CONCORD study; gastric cancer; National Program of Cancer Registries 
(NPCR); population-based cancer survival; stomach cancer; Surveillance; Epidemiology; End 
Results (SEER)
INTRODUCTION
Stomach cancer was a leading cancer cause of death early in the 20th century in the United 
States.1 Both incidence and death rates for the disease declined steadily over the course of 
the last century in many high-income countries worldwide, including the United States.2,3 
The causes of the decline are not fully understood, but it has been postulated that improved 
living conditions, the widespread use of refrigerators, the decreased consumption of salt-
preserved and smoked food, and the use of antibiotics, which may eradicate Helicobacter 
pylori from the stomach mucosa, account for part of this decline.4 Although incidence rates 
are now low in the United States, stomach cancer remains an important cause of morbidity 
and mortality in black, Asian and Pacific Islander, and American Indian/Alaska Native 
populations, with approximately 23,148 new cases and 11,261 new deaths from the disease 
expected in the United States in 2013, representing approximately 1.5% of all malignant 
neoplasms.3
The molecular biology of stomach cancer is complex and varies by site and histology. It is 
classified into several subsites within the stomach: cardia (roughly the top inch of the 
stomach), fundus, body, antrum, pylorus, and lesser or greater curvature.5 Most gastric 
tumors may be classified into 2 major histologic types: diffuse and intestinal.4 The incidence 
of gastric cardia cancer has remained stable or increased and is significantly higher among 
whites than blacks and among males, especially among whites, where the male-to-female 
ratio was 5:1.5,6 Cardia carcinomas are most frequent among white males and lowest among 
females of all racial groups,5 and they have a poorer prognosis.7,8 Non-cardia carcinoma 
incidence rates among blacks, Asians and Pacific Islanders, and American Indians/Alaska 
Natives were twice and triple those among whites, respectively,5 but the incidence has been 
dropping.6,9
Jim et al. Page 2
Cancer. Author manuscript; available in PMC 2018 February 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Disease stage at diagnosis is an important predictor of prognosis.10 As for most cancers, 
stomach cancers diagnosed at an early stage have more favorable survival than disease 
identified at distant stage.11 However, stomach cancer symptoms are often non-specific, and 
the vast majority of incident stomach cancers in the United States are diagnosed at distant 
stage.12
Racial and ethnic differences in stomach cancer incidence and mortality rates have been well 
documented.5,13,14 Previous research has highlighted racial differences in survival within the 
United States, with higher survival probabilities reported among whites than among blacks 
during 1988 through 2006.15 Differences in gastric cancer survival by country have also 
been observed.10,15–17 The CONCORD-2 study established worldwide surveillance of 
cancer survival using data for over 25 million individuals diagnosed during the 15-year 
period 1995–2009, supplied by 279 population-based cancer registries in 67 countries.17 The 
CONCORD-2 study demonstrated that the 5-year, age-standardized net survival from 
stomach cancer in the United States was 29% between 2005 through 2009, having increased 
by 7% since the period 1995–1999.17 These estimates combined data for patients of all races 
and diagnosed at all stages. The objective of the current report was to use CONCORD-2 data 
to characterize differences in stomach cancer survival between whites and blacks in the 
United States by state and by disease stage at diagnosis. To our knowledge, this is the largest 
study to date, covering 80% of the US population, thus providing a baseline set of survival 
estimates just before implementation of the Affordable Care Act from 2010.
MATERIALS AND METHODS
Data Source
We used data from 37 state-wide cancer registries funded either by the Centers for Disease 
Control and Prevention’s National Program of Cancer Registries (NPCR) (Fig. 1, dark-
colored bars) and/or the National Cancer Institute’s Surveillance, Epidemiology, and End 
Results (SEER) program (Fig. 1, pale-colored bars), or both (Fig. 1, asterisk).18 These 
registries participated in the CONCORD-2 study,17 and consented to the inclusion of their 
data in the more detailed analyses reported here. We analyzed individual tumor records for 
adults (ages 15–99 years) who were diagnosed with a primary, invasive cancer of the 
stomach (International Classification of Diseases for Oncology, third revision (ICD-O-3)19 
codes C16.0–C16.6 and C16.8–C16.9) between 2001 through 2009 and followed up to 
December 31, 2009. We included all stomach cancers, regardless of whether the patient had 
had a previous cancer. If an individual was diagnosed with 2 or more cancers of the stomach 
between 2001 through 2009, however, then only the first was considered in the survival 
analyses.
Patients were grouped by year of diagnosis into 2 calendar periods (2001–2003 and 2004–
2009) to reflect changes in the methods used by US registries to collect data on stage at 
diagnosis. From 2001, most cancer registries coded stage directly from the source data to 
SEER Summary Stage 2000.20 From 2004, all registries began to derive SEER Summary 
Stage 2000 data using the Collaborative Stage System.21
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Statistical Analyses
We estimated net survival up to 5 years after diagnosis with 95% confidence intervals (CIs) 
using the Pohar Perme estimator.22We analyzed survival by black and white race, stage at 
diagnosis, calendar period of diagnosis, and state.Net survival is interpreted as the 
probability of survival up to a given time since diagnosis, after controlling for other causes 
of death (background mortality). To control for wide differences in background mortality 
among participating states, we constructed life tables of all-cause mortality in the general 
population for each state from the number of deaths and the population, by single year of 
age, calendar year, and race (black, white), using a flexible Poisson model.23 The life tables 
have been published.24
We estimated net survival using the cohort approach for patients diagnosed between 2001 
through 2003, because all patients had been followed for at least 5 years by December 31, 
2009. We used the complete approach to estimate net survival for patients diagnosed 
between 2004 through 2009, because 5 years of follow-up data were not available for all 
patients. Net survival was estimated for 5 age groups (ages 15–44, 45–54, 55–64, 65–74, and 
75–99 years). We obtained age-standardized survival estimates using the International 
Cancer Survival Standard weights.25 If 2 or more of the 5 age-specific estimates could not 
be obtained, then we present only the pooled, unstandardized net survival estimate for all 
ages combined.
Trends, geographic variations, and differences in age-standardized net survival by race are 
presented graphically in bar charts and funnel plots.26 Funnel plots are graphic 
representations designed to detect excessive variation in performance indicators by simple 
visual inspection of the data.27 A funnel plot comprises 4 elements26: the target (or 
reference) value for the outcome, a set of control limits (the funnel), data points for the 
outcome variable (indicator), and the associated precision parameter for each data point. 
Data points outside the control limits (the funnel) indicate variation in the indicator beyond 
what would be expected by chance while taking account of precision.27 Funnel plots of net 
survival for the periods 2001 through 2003 and 2004 through 2009 provide insight into the 
variability of cancer survival in the United States by race and state. They show how much a 
particular survival estimate deviates from the pooled estimate of US registries (horizontal 
line) given the precision of each estimate. More details on data and methods are provided in 
the accompanying article by Allemani et al.28
RESULTS
We present the results for all patients diagnosed with stomach cancer in the areas covered by 
the 37 registries in Tables 1, 2 and 3. Results by state are presented in Supporting Tables 1, 
2, and 3. In total, 150,700 stomach cancers were diagnosed in the study population between 
2001 and 2009: 76.2% were diagnosed in whites, and 15.4% were diagnosed in blacks 
(Table 1). Overall, for 2004 through 2009, 30.8% of these cancers were diagnosed at a 
distant stage, 28.8%at regional, 24.9%were localized, and the remaining cancers (15.4%) 
were of unknown stage. Differences in the proportions of each stage by race between 2004 
through 2009 were ≤1%. Case counts by state over the 9-year period as indicated in 
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Supporting Table 1, ranged from a minimum of 227 (Wyoming) to a maximum of 23,247 
(California).
Absolute changes in 5-year age-standardized net survival between 2001 through 2003 and 
2004 through 2009 by US geographic region and state are illustrated in Figure 1. For all 
states combined, there was an increase of 2.9% in 5-year age-standardized net survival 
between these 2 periods. Although age-standardized 5-year net survival increased in 29 of 
the 37 states, the pooled survival estimate for all 37 states combined was low for both 
periods (26.1% and 29%, respectively) (Fig. 1).
The 1-year, 3-year, and 5-year survival estimates for patients diagnosed between 2004 
through 2009 were 53.1%, 33.8%, and 29%, respectively (Table 2). There were no 
meaningful differences in survival between blacks and whites when all 37 states were 
combined. Some states exhibited substantial in-state differences between blacks and whites; 
however, there were no discernible geographic patterns to the differences (Supporting Table 
2). The 5-year age-standardized net survival improvement by race from the first to the 
second period was 3.1% for whites and 2.2% for blacks, resulting in a slight divergence in 
survival between blacks and whites over time. The differences in 5-year net survival between 
whites and blacks indicate that there were no differences in short-term survival but that 
differences between races could widen over time.
Five-year age-standardized net survival by disease stage (Table 3) for 2004 through 2009 
was 64%, 28.2%, and 5.3% for patients with localized, regional, and distant disease, 
respectively. Improvements in 5-year net survival by stage at diagnosis were observed 
between the 2 periods for both whites and blacks. At the localized stage, there were no racial 
differences in survival, and increases of 3% were observed for both races. At the regional 
stage, survival increased by 3.4% among whites but by only 1.3% among blacks. At the 
distant stage, the increase between the 2 periods was 0.5% for whites and 1% for blacks. 
Whereas blacks experienced lower survival than whites when diagnosed at the regional 
stage, this was not the case at the distant stage, in which whites experienced lower survival 
than blacks. Five-year age-standardized survival was uniformly low across all states 
(Supporting Table 3).
Funnel plots were used to illustrate state-specific and race-specific 5-year age-standardized 
stomach cancer net survival in relation to the precision of the survival estimate. The pooled 
(US) survival estimates for each calendar period (2001–2003 and 2004–2009, 26.1% and 
29%, respectively) are indicated by the solid lines in Figure 2. Five-year, age-standardized 
net survival was similar for whites (Fig. 2, open circles) and blacks (Fig. 2, closed circles) 
from 2001 through 2003. For the period from 2004 through 2009, similar patterns were 
observed, although the aggregates tended to be less clustered, with larger survival 
differences, especially among white populations in more populous states (Fig. 2, right). The 
pooled net survival did improve slightly between the 2 periods, as indicated by the solid 
lines in Figure 2.
Jim et al. Page 5
Cancer. Author manuscript; available in PMC 2018 February 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
DISCUSSION
Stomach cancer incidence and mortality have been falling in the United States for decades.2 
However, despite these favorable trends, survival has remained poor.4,11,29 The current study 
provides the most comprehensive and current profile of stomach cancer survival patterns in 
the United States, which may be useful to public health and medical communities focused 
on stomach cancer research and control efforts. Our findings suggest that there has been only 
a very modest improvement in stomach cancer survival in recent years. Furthermore, unlike 
other cancers that were included in the CONCORD-2 study, we did not observe a large 
difference in survival or disease stage at diagnosis between whites and blacks. Examination 
of survival by sex, anatomic sub-site and histology was outside the scope of this report, and 
this may partly explain the lack of survival disparity observed between blacks and whites.
Racial and ethnic differences in the incidence and mortality for stomach cancer exist, with 
rates greater in males than in females.14,30 US cancer statistics estimates that incidence rates 
are 1.7 times higher in blacks than whites, and mortality rates are 2.0 times higher in blacks 
than in whites.3 SEER data indicate that the stomach cancer burden in the population has 
been decreasing in the United States.14,31 The National Center for Health Statistics mortality 
trend from 1984 to 2008 consistently declined by 30% to 40% in all racial or race-sex 
groups, and differences in mortality became smaller.31 SEER incidence trends from 1974 
through 1978 to 2004 through 2008 exhibited a steady decline in all racial or race-sex 
groups that was consistent with the decline in mortality.31 An increased incidence among 
young white populations in the United States has also been observed in SEER data9 but 
requires further exploration. The reductions in death rates from stomach cancer parallel a 
reduction in incidence rates.
Previous studies indicated that the decreases in stomach cancer incidence in the United 
States may be attributed to declines in distal (noncardia) and intestinal tumors.5,32 The 
intestinal type at noncardia sites is often identified in males and older adults, and the 
declining rates could be because of decreases in H. pylori infection during childhood and the 
use of refrigeration instead of salt to preserve foods.4,7,9,33 The higher incidence rates of 
noncardia carcinoma in blacks may reflect higher prevalence of H. pylori infection in this 
population.30 Cardia stomach cancers, which are more often of the diffuse histologic 
subtype, occur in all age groups and have been increasing in both males and females.32,33 
The diffuse type was consistently more common among blacks than among whites.5 The 
diffuse type is harder to detect early, which results in a poorer prognosis.32 If cardia and/or 
diffuse tumors increase as a proportion of the total tumors, then it is possible that overall 
survival will decrease for gastric cancer.
The distribution of tumors by subsite, for all participating states combined, was 33.8% and 
46.2%, for cardia and noncardia sites respectively, for whites, and 11.5% and 62.1%, 
respectively, for blacks (data not shown). On the basis of these distributions, it is likely that 
racial differences in survival exist but are being masked because survival has not been 
examined by anatomic subsite.
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Although stomach cancer has a poor prognosis, the increases in overall survival for all stages 
between the 2 periods are positive, especially because there was an increase in the 
proportion of the types with the worst prognosis—cardia and diffuse—in the total pool of 
stomach cancers. The improvement in survival for each stage could be because of better 
therapy regimens or more access to appropriate treatment.10,34,35
Some common risk factors for both cardia and noncardia carcinoma of the stomach include 
alcohol consumption, foods preserved by salting, older age, male gender, tobacco smoking, 
race, family history, low physical activity, low fiber intake, and radiation.4,33 Risk factors 
associated with cardia carcinomas include obesity and gastroesophageal reflux disease.4,33 
During 2011 through 2014, the prevalence of obesity was just over 36% in adults and 17% 
in younger adults, and it was higher among females than males.36 Between 1999–2000 and 
2013–2014, a significant increase in obesity was observed in both adults and youth.36 With 
obesity on the rise and cardia tumors likely to increase with their worse prognosis, the future 
burden of stomach cancer may increase.37,38 Risk factors associated with noncardia 
carcinomas include infection with H. pylori, low socioeconomic status, consumption of 
processed meat, high intake of salty and smoked food, and low consumption of fruits and 
vegetables.4,33,39–42
Overall, in the current study, we observed a small increase in survival between 2001–2003 
and 2004–2009. This may be related to the increase in locally staged cancers; however, most 
stomach cancers are diagnosed when they are already at a distant stage, and that proportion 
is increasing (Table 1), at the expense of regional and unknown stages. The increase in 
locally staged cancer could be related to heightened awareness in the clinical community. 
More studies are needed to understand why survival is increasing despite the absence of 
improving stage distribution and the decreasing trend in subcategories with a good 
prognosis.
Clinical Perspective
Stomach cancer symptoms are often non-specific; consequently, most patients present at an 
advanced stage. Diagnosis is by endoscopy and biopsy; computed tomography scans of the 
chest, abdomen, and pelvis are required to determine stage at diagnosis.43 Adjuvant 
chemotherapy and chemoradiotherapy after resection of stomach cancer offer survival 
benefits, but the discrepancies between the surgical technique and type of adjuvant 
chemotherapy used in clinical trials and survival probabilities have resulted in different 
adjuvant treatment protocols.34 The major challenge for clinicians is treatment sequence.34 
New studies are needed to determine the best therapy. More effective therapy is needed, as 
evidenced by the low survival and only modest improvement during 2001–2009.
Cancer-Control Perspective
Given the low stomach cancer survival observed in all states, cancer-control efforts directed 
at primary prevention through the control of well established risk factors, such as avoidance 
of smoking, maintaining a healthy weight, being physically active, eating a healthy diet 
(avoiding processed meat and limiting salt intake), and limiting alcohol consumption, may 
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have an impact on reducing the burden of stomach cancer.4,33 Currently, there is inadequate 
evidence to support screening for stomach cancer.
Strengths and Limitations
Several limitations could impact the interpretation of these findings. First, the NPCR 
registries that participated in the CONCORD-2 study conducted linkage with their state vital 
records to obtain information on deaths that occurred within their state and with the Centers 
for Disease Control and Prevention’s National Death Index to obtain information on deaths 
that occurred anywhere in the United States. Reliance on deaths reported by state vital 
records or the National Death Index may miss deaths that occur in patients who leave the 
United States between the time of their diagnosis and death. Therefore, survival estimates 
for whites in Figure 2 for the states indicated above the upper limit of the US survival 
estimate in the second calendar period may need to be interpreted with caution because of 
issues related to follow-up. Missing deaths, especially for foreign-born blacks as well as for 
Hispanic whites, can impact the estimates.28,44–46 Second, the manner in which SEER 
Summary Stage 2000 data were collected and reported changed for all registries in 2004.17 
The impact of this change was most evident among NPCR-funded registries, in which the 
percentage of patients with unknown stage decreased slightly from around 2004. Third, in 
addition to stage, stomach cancer survival depends on anatomic site and histologic type. 
Cancers located in the cardia or cancers of the diffuse Lauren histologic type have a worse 
prognosis than noncardia and intestinal types, respectively. Moreover, the proportion of 
cardia tumors is higher among whites than among blacks, as indicated in our examination of 
the distribution of tumors by subsite. In this study, survival was not analyzed by these tumor 
features; comparisons by race require further study. Fourth, stomach cancer survival was not 
analyzed by sex for this study, although evidence does indicate that women have better 
survival from stomach cancer than men.16,47 Finally, analyses of net survival by race were 
restricted to whites and blacks, the 2major racial groups in the United States, because robust 
life tables for other races and Hispanics were not available.
Conclusions
Our results indicate that stomach cancer survival is low but appears to be increasing and is 
similar to the survival pattern reported in Europe.29 We did not observe a large difference in 
survival between blacks and whites, but the difference widened slightly between 2001–2003 
and 2004–2009. Primary prevention through the control of well-established risk factors will 
be an important public health action for the longer term.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Stomach cancer: age-standardized 5-year net survival (%) for males and females (ages 15–
99 years) who were diagnosed from 2001 to 2003 and from 2004 to 2009, with absolute 
changes (%). Survival estimates for each state are ranked within US Census Region by the 
survival estimate for 2004 to 2009. Dark-colored bars denote states affiliated with the 
National Program of Cancer Registries; pale-colored bars denote states affiliated with the 
Surveillance, Epidemiology, and End Results Program. An asterisk denotes states affiliated 
with both federal surveillance programs. †indicates the percentage change was not plotted if 
a survival estimate was not available for 1 calendar period or if 1 or more estimates were not 
age-standardized.
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Figure 2. 
Stomach cancer: age-standardized 5-year net survival (%) for males and females (ages 15–
99 years) by state, race, and calendar period of diagnosis. The pooled survival estimate for 
all 37 states combined in each calendar period is indicated by a solid horizontal line, and 
corresponding 95% and 99.8% control limits are indicated by dashed lines.
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